Expertise in
10
conditions

Bingyin Y. Shi

277 West Yanta Road, 
Xi'an, CN 
Expertise in
10
conditions
277 West Yanta Road, 
Xi'an, CN 

Overview

Bingyin Shi practices practicing medicine in Xi'an, China.

Shi is highly rated in 10 conditions, according to our data. Their clinical expertise encompasses Graves Disease, Hyperthyroidism, Thyroid Cancer, Kidney Transplant, and Thyroidectomy.

They are actively involved in clinical research, co-authoring 223 peer reviewed articles and participating in 5 clinical trials.

Locations

277 West Yanta Road, Xi'an, 710061, China
Other Locations
277 Yanta West Road, Xi'an, 710061, China
No. 277, Yanta West Road, Xi'an, 710061, China
1Department Of Endocrinology, No.277, Yanta West Road, Xi'an, 710061, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Phase 3, Open-label Trial Comparing the Effect of Tirzepatide Once Weekly Versus Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Metformin With or Without a Sulfonylurea
A Randomized, Phase 3, Open-label Trial Comparing the Effect of Tirzepatide Once Weekly Versus Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Metformin With or Without a Sulfonylurea
Enrollment Status: Completed
Publish Date: January 06, 2023
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Glargine
Study Phase: Phase 3
Effectiveness and Safety of Berberine Hydrochloride and Bifidobacterium in People With Abnormal Glucose Level: an Multicenter, Randomized, Double-blinded, Placebo-controlled Study.
Effectiveness and Safety of Berberine Hydrochloride and Bifidobacterium in People With Abnormal Glucose Level: an Multicenter, Randomized, Double-blinded, Placebo-controlled Study.
Enrollment Status: Completed
Publish Date: March 15, 2021
Intervention Type: Drug
Study Phase: Not Applicable
Phase III Study of Chiglitazar in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control Despite Diet and Exercise -- A Multicenter, Randomized, Double-Blind, and Sitagliptin-Controlled Trial
Phase III Study of Chiglitazar in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control Despite Diet and Exercise -- A Multicenter, Randomized, Double-Blind, and Sitagliptin-Controlled Trial
Enrollment Status: Completed
Publish Date: October 25, 2019
Intervention Type: Drug
Study Phase: Phase 3
Effects of Berberine Hydrochloride and Bifidobacterium in Diabetes Mellitus Prevention and Treatment：an Open-label, Multicenter，Randomized, Prospective，Controlled Study
Effects of Berberine Hydrochloride and Bifidobacterium in Diabetes Mellitus Prevention and Treatment：an Open-label, Multicenter，Randomized, Prospective，Controlled Study
Enrollment Status: Withdrawn
Publish Date: November 14, 2018
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Effects of Berberine Hydrochloride and Bifidobacterium in Prediabetes Prevention and Treatment：an Open-label, Multicenter，Randomized, Prospective，Controlled Study
Effects of Berberine Hydrochloride and Bifidobacterium in Prediabetes Prevention and Treatment：an Open-label, Multicenter，Randomized, Prospective，Controlled Study
Enrollment Status: Withdrawn
Publish Date: November 14, 2018
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 4 Less Clinical Trials

223 Total Publications

Efficacy of maintenance therapy with or without pembrolizumab in patients with advanced gastric cancer after first-line chemotherapy
Efficacy of maintenance therapy with or without pembrolizumab in patients with advanced gastric cancer after first-line chemotherapy
Journal: Zhonghua yi xue za zhi
Published: September 07, 2026

Frequently Asked Questions about Bingyin Y. Shi

Is Bingyin Y. Shi a top-rated expert for Graves Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Bingyin Y. Shi is classified as an Distinguished expert for Graves Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Bingyin Y. Shi participate in research or clinical trials?

Yes. Bingyin Y. Shi has published 223 articles and abstracts on conditions like Graves Disease. You can view a list of Bingyin Y. Shi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Shi's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 38 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile